This may illustrate the benefits of genetic screening for variants in m2R-RGS6-IKACh pathway in an effort to reduce the risks of inducing dysrhythmia and/or severe bradycardia, when exposed to pharmacological treatments that elevate parasympathetic tone. The gene discussed is RGS6; the disease is cardiac arrhythmia.